Search clinical trials for: Dapagliflozin/metformin XR 10/1000mg

Total 525 results

AstraZeneca

Completed

The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

Healthy Subjects in Fasted and Fed State

Brazil
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets

Healthy

United States
Handok Inc.

Completed

A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs

Healthy Volunteers

Korea, Republic of
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
AstraZeneca
Parexel

Completed

A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

Type 2 Diabetes Mellitus

United States
Dong Wha Pharmaceutical Co. Ltd.

Completed

Pharmacokinetic Profiles of Metformin With DW1029M (PMD)

Healthy

Korea, Republic of
University of Guadalajara

Recruiting

Effect of Dapagliflozin/Metformin XR vs Monotherapies on Anthropometric Indicators in Obesity

Obesity

Mexico
Dong-A ST Co., Ltd.

Unknown

A Clinical Trial to Evaluate the Preference Regarding Convenience of Medication and Efficacy/Safety of SUGAMET®XR Tablet 5/1000mg

Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic Disease | Renal Disease

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Chong Kun Dang Pharmaceutical

Completed

A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers

Diabetes Mellitus, Type II

Korea, Republic of
Brigham and Women's Hospital

Unknown

Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

Diabetes Mellitus, Type 2

United States
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Garvan Institute of Medical Research
National Health and Medical Research Council, Australia

Recruiting

Preventing Cognitive Decline With Metformin (MetMemory)

Cognitive Decline

Australia
Beni-Suef University

Recruiting

of Sodium Glucose Cotransporter-2 Inhibitors on Metabolic, Hormonal and Clinical Parameters in PCO

PCO

Egypt
Woman's
AstraZeneca

Completed

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women (DAPA-GDM)

Diabetes Prevention in Women After GDM Who Are at High-risk

United States
AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise

Diabetes Mellitus, Type 2

United States, Ukraine, Argentina, Mexico, Romania, South Africa, Korea, Republic of, Russian Federation, Brazil, Puerto Rico, Hungary, Slovakia, Czechia
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Yooyoung Pharmaceutical Co., Ltd.

Active, not recruiting

Clinical Trial to Assess the Efficacy and Safety of YYC405 in Type 2 Diabetes Patients

Type 2 Diabetes

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Dapagliflozin When Added to Ongoing Metformin and Evogliptin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type 2 Diabetes

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Boehringer Ingelheim

Completed

Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets

Healthy

Canada
AstraZeneca
Biocard

Completed

An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions

Diabetes Mellitus, Type 2

Russian Federation
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fed State

Healthy

Korea, Republic of
Dong-A ST Co., Ltd.

Completed

Phamacokinetics and Safety Profiles of DA-5210 10/1000mg in Healthy Subjects at Fasting State

Healthy

Korea, Republic of
AstraZeneca
Bristol-Myers Squibb

Completed

Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes

Type 2 Diabetes Mellitus

Korea, Republic of, United States, Mexico, India, Puerto Rico, Russian Federation
Joint Stock Company "Farmak"

Completed

Fasting Bioequivalence Study of 2 Metformin 1000 mg Prolonged Release Tablets in 28 Healthy Male and Female Volunteers

Pharmacokinetics

Czechia
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant (EPIK-B4)

Breast Cancer

Malaysia, United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Dong-A ST Co., Ltd.

Completed

Efficacy and Safety of Evogliptin When Added to Ongoing Metformin and Dapagliflozin Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control

Type2 Diabetes

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Bristol-Myers Squibb

Completed

Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus

South Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
National Taiwan University Hospital

Recruiting

SGLT2 Inhibitors in Patients With ADHF During Ventilator Weaning

Ventilator Lung | Heart Failure Acute

Taiwan
AstraZeneca
Bristol-Myers Squibb

Completed

An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets

Type 2 Diabetes

Korea, Republic of, United States, Mexico, Puerto Rico, Philippines, Russian Federation, Ukraine
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
AstraZeneca
Bristol-Myers Squibb

Completed

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

Type 2 Diabetes Mellitus (T2DM)

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Merck KGaA, Darmstadt, Germany

Completed

Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes (CONSENT)

Diabetes Mellitus, Type 2

Germany
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Active, not recruiting

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Monoclonal Gammopathy of Undetermined Significance | Smoldering Multiple Myeloma

United States
The University of Queensland

Recruiting

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

Autosomal Dominant Polycystic Kidney Disease

Australia
Eli Lilly and Company

Completed

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus (AWARD-10)

Type 2 Diabetes Mellitus

Czechia, Hungary, United States, Mexico, Germany, Austria, Israel, Puerto Rico, Spain
AstraZeneca

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function (BalanceD-HF)

Heart Failure and Impaired Kidney Function

Spain, United States, France, Germany, Italy, Argentina, Czechia, Vietnam, Peru, China, Philippines, Saudi Arabia, Taiwan, Australia, Austria, Canada, Japan, Malaysia, Poland, Thailand, Israel, Brazil, Finland, Greece, United Kingdom, Mexico and more
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
Dexa Medica Group

Completed

PCOS Treatment Using DLBS3233, Metformin, and Combination of Both (POSITIF)

Insulin Resistance | Polycystic Ovary Syndrome (PCOS)

Indonesia

3

Subscribe